Sky View Investment Advisors, LLC Incyte Corp Transaction History

Sky View Investment Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 16, 2023	SELL	$57.77 - $65.93 $346 - $395	-6 Reduced 1.21%	489 $28,000
Q2 2023 Aug 15, 2023	SELL	$60.95 - $75.51 $287,623 - $356,331	-4,719 Reduced 90.51%	495 $69,000
Q1 2023 May 18, 2023	BUY	$70.23 - $86.01 $5,548 - $6,794	79 Added 1.54%	5,214 $377,000
Q4 2022 Feb 16, 2023	BUY	$67.18 - $84.11 $4,971 - $6,224	74 Added 1.46%	5,135 $412,000
Q3 2022 Nov 16, 2022	BUY	$66.18 - $82.86 $47,517 - $59,493	718 Added 16.53%	5,061 $337,000
Q2 2022 Nov 15, 2022	SELL	$66.18 - $83.18 $46,921 - $58,974	-709 Reduced 14.03%	4,343 $330,000
Q1 2022 May 17, 2022	SELL	$66.02 - $79.71 $20,202 - $24,391	-306 Reduced 5.71%	5,052 $401,000
Q4 2021 Feb 18, 2022	SELL	$63.34 - $74.11 $159,743 - $186,905	-2,522 Reduced 32.01%	5,358 $335,000
Q3 2021 Nov 16, 2021	BUY	$68.67 - $84.02 $510,218 - $624,268	7,430 Added 1651.11%	7,880 $542,000
Q1 2021 May 18, 2021	BUY	$76.02 - $100.5 $28,735 - $37,989	378 Added 525.0%	450 $37,000
Q4 2020 Mar 02, 2021	BUY	$80.74 - $97.7 $5,813 - $7,034	72 New	72 $6,000

659

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.4B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Sky View Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Sky View Investment Advisors, LLC with notifications on news.